Search results for "Adverse Drug Reaction Reporting Systems"

showing 10 items of 13 documents

Experiences of a Poison Center Network with Renal Insufficiency in Acetaminophen Overdose: An Analysis of 17 Cases

2005

Renal insufficiency is less common than liver failure in acetaminophen overdose but renal tubular damage occurs even in the absence of hepatotoxicity. Data published on this topic are rare consisting mostly of case reports or reports in a small number of patients. Presently, a larger number of patients with renal insufficiency associated with acetaminophen overdose should be analyzed using a multicenter approach.Retrospective analysis of patients with acetaminophen-related nephrotoxicity reported to a poison center network from 1995 to 2003. Renal insufficiency was defined as elevated serum creatinine of more than double of the normal range (2.4 mg/dL [212 micromol/L]). Patients were classi…

AdultMalemedicine.medical_specialtyPediatricsPoison Control Centersacetaminophen overdoseAdolescentInjury controlPoison controlurologic and male genital diseasesToxicologyGermanymedicineAdverse Drug Reaction Reporting SystemsHumansRenal InsufficiencyAntipyreticIntensive care medicineAcetaminophenAgedbusiness.industryLiver failureGeneral MedicineAnalgesics Non-Narcoticmedicine.diseaseAcetaminophenFemaleDrug OverdoseDrug intoxicationbusinessmedicine.drugKidney diseaseClinical Toxicology
researchProduct

Cataracts and statins. A disproportionality analysis using data from VigiBase.

2019

The basis of the association between statin use and cataract has been explored using the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) through January 2019. The reporting odds ratios (RORs) as a measure of disproportionality for reported cataracts and individual statins have been calculated. Subgroup analyses according statin lipophilicity, sex, and age groups have been performed. Moreover, RORs have been calculated for non-statin lipid lowering drugs. An increased disproportionality have been found for most individual statins lovastatin: [ROR: 14.80, 95% confidence interval (CI): 13.30, 16.46)], atorvastatin (ROR: 3…

AdultMalemedicine.medical_specialtyStatinAdolescentmedicine.drug_classAtorvastatin010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentCataract03 medical and health sciencesPharmacovigilanceYoung Adult0302 clinical medicineEzetimibeInternal medicinemedicineOdds RatioAdverse Drug Reaction Reporting SystemsHumansRosuvastatinChild0105 earth and related environmental sciencesAgedAged 80 and overbusiness.industryIncidenceGeneral MedicineOdds ratioMiddle AgedSimvastatinFemaleDrug MonitoringHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatinRegulatory toxicology and pharmacology : RTP
researchProduct

Validation of the French national health insurance information system as a tool in vaccine safety assessment: Application to febrile convulsions afte…

2013

In the French national health insurance information system (SNIIR-AM), routine records of health claimed reimbursements are linked to hospital admissions for the whole French population. The main focus of this work is the usability of this system for vaccine safety assessment programme. Self-controlled case series analyses were performed using an exhaustive SNIIR-AM extraction of French children aged less than 3 years, to investigate the relationship between MMR immunization and children hospitalizations for febrile convulsions, a well-documented rare adverse event, over 2009-2010. The results suggest a significant increase of febrile convulsions during the 6-11 days period following any MM…

RiskPediatricsmedicine.medical_specialtyNational Health ProgramsMeasles-Mumps-Rubella VaccinePopulationRate ratioSeizures FebrilePneumococcal conjugate vaccine03 medical and health sciences0302 clinical medicine030225 pediatricsProduct Surveillance PostmarketingAdverse Drug Reaction Reporting SystemsHumansMedicine030212 general & internal medicineeducationAdverse effectImmunization ScheduleComputingMilieux_MISCELLANEOUSeducation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantICD-103. Good healthHospitalizationVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular Medicine[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusiness[STAT.ME]Statistics [stat]/Methodology [stat.ME]Measles-Mumps-Rubella Vaccinemedicine.drug
researchProduct

Natalizumab: a country-based surveillance program

2008

Natalizumab is a humanized monoclonal antibody with a selective adhesion-molecule inhibitor effect, and a demonstrated efficacy in decreasing the frequency of relapses and progression of disability in relapsing-remitting multiple sclerosis (RR MS). After the approval of FDA and EMEA in MS cases unresponsive to immunomodulating therapy or in severe MS patients also not previously treated with interferons, and considering the concern on the possible side effects, an accurate program of surveillance was organized in our country by a combined effort of AIFA, Cineca, Department of Pharmacology of University of Bologna, and a group of neurologists appointed by the National Society of Neurology (S…

AdultMalemedicine.medical_specialtyNeurologyDatabases FactualDrug-Related Side Effects and Adverse ReactionsNational Health ProgramsDrug ResistanceDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabInternal medicineOutcome Assessment Health CareMultiple SclerosiPharmacovigilanceProduct Surveillance PostmarketingmedicineAdverse Drug Reaction Reporting SystemsHumansImmunologic FactorsMULTIPLE SCLEROSISNATALIZUMABClinical Trials as Topicbusiness.industryMultiple sclerosisAntibodies MonoclonalMean ageGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyREGISTRYPHARMACOVIGILANCEPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessPreviously treatedFollow-Up Studiesmedicine.drug
researchProduct

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.

2021

International audience; In this special issue, we present the main highlights of the first weeks of pharmacovigilance monitoring of coronavirus disease 2019 (COVID-19) vaccines in this unprecedented situation in France: the deployment of a vaccination during an epidemic period with the aim of vaccinating the entire population and the intense pharmacovigilance and surveillance of these vaccines still under conditional marketing authorizations. In this unprecedented situation, the cross approach and interaction between the French pharmacovigilance network and French National Agency for the Safety of Medicines and Health Products (ANSM) has been optimized to provide a real-time safety related …

MaleEuropean levelCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Adverse drug reactions030226 pharmacology & pharmacyArticleADR adverse drug reaction03 medical and health sciencesPharmacovigilance0302 clinical medicinePharmacovigilancePandemicMedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)Drug reactionPEG polyethylene glycolEntire populationVaccinesbusiness.industrySOC system organ classSARS-CoV-2COVID coronavirus disease[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/NeuroscienceAuthorizationCOVID-19Middle Agedmedicine.diseaseRPVC Regional Pharmacovigilance CenterVaccinationEMA European Medicines AgencyFemaleMedical emergencyFrancebusinessANSM Agence nationale de sécurité du médicament et des produits de santé (French National Agency for the Safety of Medicines and Health Products)OrganizationTherapie
researchProduct

Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system

2016

Objectives: The surveillance of vaccine safety is an essential requirement in vaccination programmes. Computerized immunization registries such as the Vaccination Information System (SIV) of Valencian Community (Spain) offer the opportunity to estimate the incidence of adverse events according to individual information. The aim of the study was to analyze adverse events following immunization reported through SIV from 2005 to 2011 by age, sex, type of vaccine and dose, and adverse event, and highlight the advantages of this type of reporting. Study design: A retrospective cohort study of subjects vaccinated in the Valencian Community using population health databases was carried out. Method…

AdultMaleVaccine safetyPediatricsmedicine.medical_specialtyAdolescentDatabases FactualImmunization registryPopulation healthYoung Adult03 medical and health sciences0302 clinical medicine030225 pediatricsProduct Surveillance PostmarketingAdverse Drug Reaction Reporting SystemsHumansMedicine030212 general & internal medicineYoung adultChildAdverse effectAgedRetrospective StudiesVaccinesbusiness.industryIncidence (epidemiology)Public Health Environmental and Occupational HealthInfantRetrospective cohort studyGeneral MedicineMiddle AgedPassive surveillanceVaccinationAEFI (adverse event following immunization)ImmunizationSpainChild PreschoolFemaleSafetybusinessImmunization registry
researchProduct

Nationwide evaluation of day-to-day clinical pharmacists' interventions in German hospitals.

2015

tudy Objective To describe and evaluate the extent and diversity of nationwide data from clinical pharmacists’ interventions (PIs) in German hospitals. Design Retrospective analysis. Data Source The ADKA-DokuPIK German database, a national anonymous self-reported Internet-based documentation system for routine PIs as well as for medication errors reported by German hospital pharmacists. Measurements and Main Results Data sets from ADKA-DokuPIK entered between January 2009 and December 2012 were analyzed descriptively. A total of 27,610 PIs were entered, mainly by ward-based clinical pharmacists (82.5%). Most of the PIs were performed on surgical wards (37.8%), followed by anesthesiology/int…

Data sourcemedicine.medical_specialtyDatabases Factualbusiness.industryPsychological interventionIntensive care unitlanguage.human_languagelaw.inventionGermanClinical pharmacySafety-Based Drug WithdrawalslawAnesthesiologyGermanyAntithromboticEmergency medicinemedicinelanguageAdverse Drug Reaction Reporting SystemsHumansMedication ErrorsPharmacology (medical)Day to daybusinessPharmacy Service HospitalPharmacotherapy
researchProduct

Dydrogesterone use during pregnancy: Overview of birth defects reported since 1977

2009

Between 1977 and 2005, 28 cases of potential links between maternal dydrogesterone use during pregnancy and congenital birth defects were reported. The types of defects were very diverse, with no evidence of a pattern of abnormalities. The data do not provide evidence for congenital malformations associated with dydrogesterone use.

Gynecologymedicine.medical_specialtyPregnancyProgestogenObstetricsbusiness.industrymedicine.medical_treatmentAbnormalities Drug-InducedObstetrics and GynecologyCongenital malformationsDydrogesteronemedicine.diseaseMaternal ExposurePregnancyPediatrics Perinatology and Child HealthDydrogesteronemedicineAdverse Drug Reaction Reporting SystemsHumansGestationFemaleProgestinsbusinessmedicine.drugEarly Human Development
researchProduct

Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Usin…

2015

Drug-induced liver injury is a major problem of pharmacotherapy and is also frequent with antidepressive psychopharmacotherapy. However, there are only few studies using a consistent methodologic approach to study hepatotoxicity of a larger group of antidepress ants. We performed a quantitative signal detection analysis using data from the Uppsala Monitoring Centre from the WHO that records adverse drug reaction (ADR) data from worldwide sources; we retrieved substance- and country-specific (Australia, France, Germany, Italy, Spain, the United Kingdom, and the United States) ADR data and calculated reporting odds ratios as measures for disproportionality within a case/noncase approach. To a…

medicine.medical_specialtyInternationalityDatabases FactualMedDRAMirtazapineAmineptinePharmacology03 medical and health sciences0302 clinical medicineInternal medicinePharmacovigilancemedicineAgomelatineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)030212 general & internal medicinePharmacologybusiness.industryAustraliaOdds ratiomedicine.diseaseAntidepressive AgentsUnited StatesEuropeChemical and Drug Induced Liver InjuryNefazodonebusiness030217 neurology & neurosurgeryAdverse drug reactionmedicine.drugJournal of clinical pharmacology
researchProduct

Adverse drug reactions in children reported by means of the yellow card in Spain.

2000

Abstract Objective: To analyze the case reports concerning children (14 years or younger) in the Spanish Pharmacovigilance System over a 10-year period (1982–1991). Findings: The study of 1419 reports of adverse drug reaction (9.8% of all those received) showed the most commonly involved organs and systems to be the skin, digestive tract, and nervous system (62.8%). The most commonly involved pharmacological groups were antibiotics, respiratory medications, and vaccines (69%). The absolute number of reports is higher in children between 1 and 4 years of age (37.9%). There were more reports among males than in females. Less than 5% of the reports notified directly life-threatening or fatal r…

Malemedicine.medical_specialtyPediatricsAdolescentDrug-Related Side Effects and Adverse ReactionsEpidemiologymedicine.drug_classAntibioticsEpidemiologyPharmacovigilanceMedicineAdverse Drug Reaction Reporting SystemsHumansChildbusiness.industryPharmacoepidemiologyInfantPharmacoepidemiologymedicine.diseaseClinical trialEl NiñoSpainChild PreschoolEtiologyFemalebusinessAdverse drug reactionJournal of clinical epidemiology
researchProduct